Cannabigerol Modulates Blood Pressure and Vascular Reactivity in a Rat Model of Hypertension and Platelet Responses in Human Blood In Vitro.

Acute CBG administration dose-dependently lowered blood pressure and heart rate in both spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY).

• CBG was administered at doses of 1, 3, and 10 mg/kg acutely.
• The hypotensive and heart rate-lowering effects were dose-dependent across both strains.
• Effects were described as 'comparable between strains' with one notable exception.
• Systolic blood pressure reduction was greater in SHR than in WKY rats.

Experiments in pithed rats supported both central and peripheral contributions to CBG's hypotensive effect.

• Pithed rat preparations were used to help isolate peripheral versus central mechanisms.
• Results supported the possibility of 'both central and peripheral contributions to this hypotensive effect.'
• The peripheral component was further supported by direct vascular experiments on isolated arteries.

CBG induced vasorelaxation in both small mesenteric arteries (sMAs) and aortas, with the effect more pronounced in sMAs.

• Vasorelaxant effects were assessed in isolated small mesenteric arteries and aortas.
• Vasorelaxation was described as 'more pronounced in sMAs' compared to the aorta.
• Vasorelaxant effects were also more pronounced in WKY rats compared to SHR.
• These findings provide a peripheral vascular mechanism for the observed blood pressure reduction.

CBG inhibited collagen-induced platelet aggregation and secretion in human blood in vitro.

• Platelet aggregation was assessed using collagen as the inducing agent.
• CBG inhibited both platelet aggregation and secretion.
• These experiments were conducted in human blood in vitro.
• This represents one of the first reports of CBG effects on human platelet function.

CBG reduced thrombus formation and platelet procoagulant response under arterial flow conditions in human blood.

• Thrombus formation was assessed under arterial flow conditions, reflecting physiologically relevant shear stress.
• CBG reduced both thrombus formation and the platelet procoagulant response.
• These experiments were conducted in vitro using human blood.
• These findings suggest CBG may have antithrombotic properties in addition to its vasoactive effects.

CBG exerts multifaceted cardiovascular effects encompassing blood pressure regulation, vascular reactivity, and platelet function.

• The study investigated CBG effects across three cardiovascular domains: in vivo blood pressure and heart rate, ex vivo vascular reactivity, and in vitro platelet function.
• Prior literature had established CBG's vasorelaxant effects in human pulmonary arteries and blood pressure-lowering effects in normotensive mice.
• Data on cardiovascular effects of CBG in hypertension and platelet function were described as 'limited' prior to this study.
• The authors conclude that 'CBG exerts multifaceted cardiovascular effects.'